Form 4: Amicus Therapeutics Acquired by BioMarin for $14.50/Share

Director Lynn Dorsey Bleil reports the disposal of all Amicus Therapeutics equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Amicus Therapeutics (FOLD) has been acquired by BioMarin Pharmaceutical Inc.
• Director Lynn Dorsey Bleil disposed of 113,941 shares of common stock at a price of $14.50 per share.
• Multiple tranches of stock options with exercise prices ranging from $5.96 to $12.81 were cancelled and converted into cash payments based on the $14.50 acquisition price.
• All equity holdings and derivative securities previously held by the reporting person have been liquidated as part of the merger completion.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the finalization of a previously announced corporate acquisition.

Positives

• Successful completion of the merger with BioMarin Pharmaceutical Inc.
• Shareholders received a cash consideration of $14.50 per share for their holdings.
• Full vesting of all outstanding restricted stock units and stock options occurred upon the consummation of the merger.

Negatives

• The reporting person no longer holds any equity interest in Amicus Therapeutics as the company has been acquired.

Risks

• No ongoing risks as the issuer has been acquired and the reporting person has exited their position.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; therefore, no further forward-looking guidance is provided by the issuer.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the rare disease and biotechnology sector, aligning with broader trends of larger pharmaceutical firms acquiring specialized biotech entities to bolster their pipelines.

Comparison to Industry Standards

• The acquisition price of $14.50 per share reflects the final valuation agreed upon by the boards of both Amicus Therapeutics and BioMarin.
• The acceleration of vesting for equity awards upon a change-in-control is standard practice in biotechnology M&A transactions.

Stakeholder Impact

• Shareholders have received cash proceeds for their equity positions.
• The reporting person has ceased their role as a director due to the acquisition.

Next Steps

• Delisting of Amicus Therapeutics common stock from public exchanges.

Key Dates

Keywords

Amicus Therapeutics, FOLD, BioMarin, Merger, Acquisition, Form 4, Insider Transaction